Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Identification of a missense mutation (G329A; Arg110→Gln)
in the human FUT7 gene
Per Bengtson1, Cecilia Larson2, Arne Lundblad1, Göran Larson2 and Peter Påhlsson1
1Department of Biomedicine and Surgery, Division of Clinical Chemistry, Linköping
University, SE-581 85 Linköping, Sweden; 2Institute of Laboratory Medicine, Department of
Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, SE-413 45
Göteborg, Sweden.
Corresponding author: Göran Larson, Institute of Laboratory Medicine, Department of
Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, SE-413 45
Göteborg, Sweden.
Tel +46-31-3421330
Fax +46-31-828458
E-mail [email protected]
Running title: FUT 7 mutation
1
Copyright 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
JBC Papers in Press. Published on June 12, 2001 as Manuscript M104165200 by guest on M
arch 6, 2020http://w
ww
.jbc.org/D
ownloaded from
Abstract
The human FUT7 gene codes for the α1,3-fucosyltransferase VII (Fuc-TVII) which is
involved in the biosynthesis of the sialyl Lewis x (SLex) epitope on human leukocytes. The
FUT7 gene has so far been considered to be monomorphic. Neutrophils isolated from patients
with ulcerative colitis were examined for apparent alterations in protein glycosylation patterns
by Western blot analysis using monoclonal antibodies directed against SLex and SLex-
related epitopes. One individual showed lower levels of SLex expression and an elevated
expression of CD65s compared to controls. The coding regions of the FUT7 gene from this
individual were cloned and a G329A point mutation (Arg 110→Gln) was found in one allele,
whereas the other FUT7 allele was of wild type. No Fuc-TVII enzyme activity was detected
in COS-7 cells transiently transfected with the mutated FUT7 construct. The FUT7 Arg110 is
conserved in all previously cloned vertebrate α1,3-fucosyltransferases. PCR followed by
restriction enzyme cleavage was used to screen 364 unselected Caucasians for the G329A
mutation and a frequency of d1% for this mutation was found (3 heterozygotes). Genetic
characterization of the family members of one of the additional heterozygotes identified one
individual carrying the G329A mutation in both FUT7 alleles. Peripheral blood neutrophils of
this homozygously mutated individual showed a lowered expression of SLex and an elevated
expression of CD65s when analyzed by Western blot and flow cytometry. The homozygous
individual was diagnosed with ulcer disease, non-insulin dependant diabetes, osteoporosis,
spondyloarthrosis and Sjögren´s syndrome but had no history of recurrent bacterial infections
2
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
or leukocytosis.
Introduction
Recruitment of leukocytes to sites of inflammation or infection is initiated by interaction of
leukocytes with activated vessel-wall endothelium leading to “rolling” of leukocytes along
endothelial cell surfaces. This interaction subsequently leads to extravasation of leukocytes
into the surrounding infected or inflamed tissue (1). E- and P-selectins, which are expressed
on activated endothelial cells, are involved in this interaction (2-4). The third member of the
selectin family, L-selectin, is involved when lymphocytes extravasate into secondary
peripheral lymphoid organs, where it interacts with counter-receptors on the post-capillary
high endothelial venules (HEV2) (5).
All three selectins recognize glycoprotein counter-receptors that must be properly
glycosylated for binding to occur. All glycans that have been described for efficient
recognition by selectins are modified by α2,3-sialylation and α1,3-fucosylation, and the
minimal common epitope for all selectins is the sialyl Lewis x (SLex , NeuAcα2-3Galß1-
4[Fucα1-3]GlcNAcß1-3-) epitope (6).
3
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
The final step in the biosynthesis of the SLex antigen involves the action of an α1,3-
fucosyltransferase (7). Of the six human α1,3-fucosyltransferases cloned so far, only three
are expressed in leukocytes; Fuc-TIV (8-10), Fuc-TVII (11,12) and the recently cloned Fuc-
TIX (13). The expression level of Fuc-TIX in human leukocytes is however significantly
lower compared to Fuc-TIV and Fuc-TVII (13).
Fuc-TIV has a wide acceptor specificity for GlcNAc in polylactosamines and sialylated
polylactosamines forming for example the Lewis x (Lex, Galß1-4[Fucα1-3]GlcNAcß1-3)
and CD65s (NeuAcα2-3Galß1-4GlcNAcß1-3Galß1-4[Fucα1-3]GlcNAcß1-3-) antigens.
The Fuc-TVII acceptor specificity is restricted to the distal GlcNAc on α2,3-sialylated
lactosamines forming the SLex antigen (14,15). Although Fuc-TIV can synthesize SLex in
vitro (14) Fuc-TVII has been proved to be crucial for the synthesis of SLex and selectin
ligands on leukocytes (16,17). In addition, Fuc-TVII expression in peripheral lymph HEV has
been correlated with expression of L-selectin ligands (5,18). Transfection of human lymphoid
cell lines by antisense cDNA to selectively down-regulate Fuc-TVII suppressed SLex
expression and E-selectin mediated binding (19). Furthermore, mice made deficient in the
Fuc-TVII enzyme showed blood leukocytosis, deficiency in expression of selectin ligand
activity, impaired neutrophil trafficking in inflammation and defects in lymphocyte
recirculation, strongly establishing a role for Fuc-TVII in selectin ligand synthesis (20).
4
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Several of the cloned α1,3-fucosyltransferases are highly polymorphic in humans. Point
mutations inactivating or disrupting Fuc-TIII (α1,3/1,4-fucosyltransferase, Lewis enzyme)
give rise to Lewis negative phenotypes (21-24). Inactivating mutations have also been found
in the FUT6 gene coding for the plasma α1,3-fucosyltransferase, Fuc-TVI (25-28).
However, there have been no reports on genetic polymorphism in the genes encoding for the
α1,3-fucosyltransferases expressed in human leukocytes.
In this paper we describe for the first time a missense mutation of the FUT7 gene associated
with an altered expression of SLex and CD65s (VIM-2) epitopes on human
polymorphonuclear leukocytes.
Materials and methods
Patients and controls
Fifteen patients with ulcerative colitis (n=13) or proctitis (n=2) were examined. Twelve
healthy controls were also studied. Restriction endonuclease analysis was performed on DNA
samples from 106 plasma donors in Göteborg (29) and 258 unselected adult individuals from
the Linköping area. A pedigree study of FUT7 genetics was performed in one Swedish
family. The study was approved by local ethical committees in Göteborg and Linköping.
Isolation of polymorphonuclear leukocytes
5
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Human polymorphonuclear leukocytes (PMN) were isolated from 10 ml of freshly drawn
EDTA anticoagulated blood using density gradient centrifugation (Polymorphprep, Nycomed,
UK). The cell preparations had a purity of >90% as determined by analyses on an automatic
cell counter (H3 instrument, Bayer Diagnostics, Germany).
Antibodies
Primary antibodies used were KM93 and CSLEX-1 directed against sialyl Lewis x (SLex),
(Serotech Ltd., Oxford, UK, and Becton Dickinson, San José, CA); VIM-2 directed against
CD65s (kindly provided by Prof. W. Knapp, University of Vienna, Vienna); 911-F11
directed against Lewis x (Lex) and 9001/1H10 directed against sialyl Lewis a (SLea)
(BioCarb AB, Lund, Sweden). For flow cytometry FITC-conjugated primary mouse antibody
against CD15 (Le x, Leu-M1, Becton-Dickinson No 347423) and control FITC-conjugated
mouse IgG1 antibody (X0927, Dako A/S Glostrup, Denmark) were used. FITC-conjugated
F(ab´)2 fragment of rabbit anti-mouse immunoglobulins (F0313, Dako A/S) were used as
secondary antibody. For immunoflourescence analyses the secondary antibody used was
fluorescein conjugated rat anti mouse Ig F261, and for Western blot analyses secondary
peroxidase conjugated rat anti mouse Ig P161 and peroxidase conjugated goat anti rabbit Ig
P448 (Dako A/S, Glostrup, Denmark) antibodies were used. Antigen purified rabbit anti-
mouse Fuc-TVII antiserum was kindly provided by Prof. J. B. Lowe (University of Michigan,
MI).
6
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Immunoblot analysis
Cell lysates were prepared by solubilizing the purified PMN in 400 µl of lysis buffer (50 mM
Tris-HCl pH 8.0; 150mM NaCl; 5 mM EDTA, 1% IGEPAL CA-630 (Sigma Inc., St. Louis,
MO) containing 0.12 µM PMSF; 2.3 µM Leupeptin and 1.5 µM Pepstatin. Protein
concentration in the supernatant was determined by the 4,4´-Dicarboxy-2,2´biquinoline,
Bicinchonicic Acid (BCA) method (30) (PIERCE, Rockford, IL). An aliquot of the
supernatant corresponding to 20 µg protein was separated by 10% SDS-PAGE (31) and
transferred to an Immobilon-P polyvinylidene fluoride microporous membrane (Millipore,
Bedford, MA, USA) (32). The membrane was blocked with Tris buffered saline (TBS, 50
mM Tris-HCl, 150 mM NaCl, pH 7.5) containing 5% Tween 20 and 5 % defatted milk
powder (Semper, Stockholm, Sweden) at room temperature for 1 hour. The membrane was
then washed twice with TBS, incubated overnight at 4°C with primary antibody in TBS, 1%
BSA, washed three times with TBS containing 0.3% Tween 20 and incubated with
peroxidase-conjugated secondary antibody in TBS containing 1% milk powder and 0.1%
Tween 20 for 1 hour at room temperature. The membrane was rinsed three times with TBS
containing 0.3% Tween 20 and positive bands were visualized using ECL Western blotting
reagents (Amersham Pharmacia, UK). For Western blot analysis of COS-7 cells the
membranes were blocked in 10% BSA in PBS containing 0.2% Tween-20 (PBS-T) over
night at 4°C. PBS-T was used for washing and PBS-T containing 3% of BSA was used for
incubations with primary and secondary antibodies.
For calculation of molecular size, prestained molecular mass standards (Bio-Rad, Hercules,
CA) were used. Digital images of the blots were analyzed using a CCD camera (512 x 512
7
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
pixels) in combination with a computerized imaging 8-bit system (Visage 4.6 from
BioImage, Ann Arbor, MI). The quantitative expression of each epitope in a lane was
assessed as background-corrected optical density, integrated over all pixels in the lane and
expressed as integrated optical density.
Molecular cloning of FUT7 cDNA
Buffy coat was isolated from freshly drawn EDTA anticoagulated blood from one
heterozygously mutated patient (M.N.). Total RNA was isolated using SV Total RNA
isolation system (Promega Corp. Madison, WI) and cDNA was prepared using oligo (dT)15
primers and Reverse Transcription System A3500 according to the manufacturers protocol
(Promega Corp.). PCR was used to amplify the coding regions and immediately adjacent 5´-
and 3´-flanking regions of FUT7 using 0.25 µg of cDNA as template. The PCR-program
used an initial temperature of 8°C for 10 min followed by 40 amplification cycles run for 15 s
at 95°C, 15 s at 59°C and 3 min at 68°C. The last extension step was kept for 10 min at 68°C.
The sense primer (25 pmol), VII-3s, 5´-gctagcgaattcCTGATCCTGGGAGACTGTGG-3´ is
complementary to nucleotides -20 to -1 and contains additional nucleotides (lowercase) at its
5´end, including an EcoRI (underlined) restriction site. The antisense primer (25 pmol) VII-
4as, 5´- gtcgactctagaGTAAGGGCCGGATGCCTGGT-3´ anneals to nucleotides 1107-1088,
and contains additional nucleotides (lowercase) at its 5´ end, including an XbaI (underlined)
restriction site. The 1151-bp PCR product was ligated into the pCR2.1 TA-cloning vector
(Invitrogen Corp., San Diego, CA). Transformation of InVαF bacteria, was performed
according to the manufacturers protocol (Invitrogen Corp.). Positive clones were identified by
8
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
blue-white screening, preparation of plasmids and cleavage with XbaI and EcoRI (Life
Technologies, Paisley, UK.). Twenty-four clones were analyzed with PCR-RFLP (PCR-
Restriction Fragment Length Polymorphism) to identify TA clones with wild type or mutated
alleles. Primer VII-15s (5´-CATCGCCCGCTGCCACCTGAGT-3´) corresponding to
nucleotides 216-237, and VII-5as (5´-GCTGCCGCTCCTGGAAGTTGCTGAC-3´)
corresponding to nucleotides 529-554, were used to amplify a 338 bp fragment of FUT7
cDNA. The G329A mutation abolishes the restriction site GC↓GGCCGC for NotI (Life
Technologies). When the 338 bp PCR product was treated with NotI and analyzed by gel
electrophoresis the wild type allele was digested into two products of 247 and 91 bp, whereas
the mutant allele remained intact. Complete sequencing of 9 TA clones was done on an Alf
II-express using the Cy5-dye terminator kit (Amersham Pharmacia Biotech Inc.). One wild
type clone and one clone containing the G329A point mutation without PCR-induced errors
were chosen for subcloning of the FUT7 insert into the pSI mammalian expression vector
(Promega Corp.). The resulting plasmid containing the FUT7 wild type was called pSI-wt
and the plasmid containing the mutated construct was called pSI-329.
Cloning of the FUT7 gene from genomic DNA
PCR was used to amplify the two coding regions and the 253 bp intron (33) as well as the
immediately adjacent 5´- and 3´- flanking regions of the FUT7 gene from DNA prepared
from whole blood. The PCR-program used an initial temperature of 85 °C for 10 min
followed by 30 amplification cycles run for 15 s at 60 °C, 15 s at 59 °C and 3 min at 68 °C.
The last extension step was kept for 10 min at 68 °C. The VII-3s sense primer (30 pmol), and
9
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
the VII-4as antisense primer (30 pmol) were used. The 1404-bp PCR product was ligated
into the pCR2.1 TA-cloning vector as above and sequenced with the AmpliTaq DNA
polymerase FS kit (Perkin-Elmer, Foster City, CA) on an Applied Biosystems 373A DNA
sequencer (Perkin-Elmer).
Transfection
COS-7 cells (~106 cells) cultured in Dulbecco´s modified Eagle’s medium supplemented
with 10% heat-inactivated fetal calf serum were transfected with 10 µg of expression vector
constructs using the DEAE-dextran method (34). The cells were transfected with pSI without
insert as a negative control or with the two pSI-FUT7 constructs (pSI-wt and pSI-329). The
medium was changed 24 hours post transfection. Transfected cells were harvested after a 96 h
growth period post transfection. Transfection efficiency was controlled using quantitative
PCR analysis. Total RNA was isolated from transfected cells according to the manufacturer’s
instructions using a Total RNA kit (Promega Corp.) including treatment with DNAse. A
reverse transcription kit (Promega Corp.) was used according to the manufacturer’s
instructions to transcribe 1 µg of total RNA.
Quantitative PCR analysis was performed using the TaqMan PCR Core Reagent Kit (PE
Biosystems, CA). Reactions for FUT7 quantification were performed in 30 µL with 0.2 µg of
cDNA; 3 µL of 10 × TaqMan Buffer A (500 mM of KCl; 100 mM of Tris-HCl, pH 8.3);
5 mM MgCl2; 200 µM each of dATP, dCTP, dGTP; 400µM dUTP; 0.3 U uracil-N-
10
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
glucosidase (UNG); 0.75 U of AmpliTaq Gold DNA polymerase; 50 nM of FUT7-probe;
and 100 nM of FUT7 sense and anti sense primers. The following FUT7 consensus primers
and probe were used: r1s, 5’-CTTGGCTGACTGACTCTGG-3’ (nucleotides –29 to -11);
r2as, 5’-CCTCGCAGCCTCCG-3’ (nucleotides 28 to 41) and FUT7-probe, 5’-
CCGTGCCCAAGCATTATTCATCCA-3’ (nucleotides –3 to 20). The FUT7-probe was
designed to cover the sequence over the splice site in FUT7 cDNA to avoid amplification of
contaminating genomic DNA sequences. As an additional control for contaminating DNA,
quantitative PCR was also performed leaving out the first RT-PCR step. This did not generate
any product. The PCR-program used an initial temperature of at 50°C for 2 min and then
95°C for 10 min, followed by 40 amplification cycles run for 15 s at 95°C and 1 min at
60°C. The amplifications were performed on an ABI Prism 7700 sequence detector equipped
with a 96-well thermal cycler. Data were collected and analyzed with Sequence Detector
v1.6.3 software (PE Biosystems). Reactions for quantifying ß-actin were performed exactly
as described above except for using 3.5 mM MgCl2 and 300 nM sense primer 5’-
TCACCCACACTGTGCCCATCTACGA-3’, 300 nM anti sense primer 5’-
CAGCGGAACCGCTCATTGCCAATGG-3’, and 200 nM ß-actin probe 5’-
ATGCCCCCCCCATGCCATCCTGCGT-3’ (PE Biosystems). All analyses were performed
in triplicates and with probes labeled with 6-carboxyfluorescein (FAM)- and 6-
carboxytetramethylrhodamine (TAMRA).
11
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Immunofluorescence analysis of Lewis antigen expression on the surface of transfected COS-
7 cells
The transfected cells were trypsinized, washed, and incubated with primary antibodies against
CD65s, SLea, SLex and Lex. After 30 min incubation with the primary antibody, the cells
were washed with phosphate-buffered saline (PBS) without Ca2+ and Mg2+ and incubated
another 30 min with fluorescein conjugated rat anti mouse IgG secondary antibody. After
incubation with the secondary antibody the cells were washed with PBS without Ca2+ and
Mg2+. The cell pellets were then fixed with Mowiol (Hoechst, Frankfurt am Main, Germany)/
paraformaldehyde (4%, pH 7.3) 1/3 (v/v) and mounted on glass. The cells were observed
under a Leitz SM-LUX epifluorescence microscope. Immunofluorescence studies were also
conducted on adherent cells in 8-well tissue culture chamber slides (Nunc Inc, Naperville, IL)
without using trypsin treatment.
Fucosyltransferase assay
Enzyme activity was analyzed by measuring the incorporation of GDP-[14C] fucose, 300
mCi/mmol (Amersham Pharmacia Biotech Inc.), to a sialylated type 2 acceptor substrate,
NeuAcα2-3Galβ1-4GlcNAcβ1-sp-biotin or a sialylated type 1 acceptor substrate,
NeuAcα2-3Galβ1-3GlcNAcβ1-sp-biotin (Syntesome, Munich, Germany) COS-7 cells transfected
with pSI, pSI-wt or pSI-329 were lysed in 50 mM MOPS buffer (pH 7.5) containing 1%
Triton X-100. Apparent Km for GDP-Fuc was determined using Lineweaver-Burk plots
12
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
with GDP-Fuc concentrations between 2 and 10 µM and an acceptor concentration of 10 mM.
Apparent Km for the sialylated type 2 acceptor was determined with acceptor concentrations
between 0.25 and 10 mM and a GDP-Fuc concentration of 100 µM. The assay was initiated
with the addition of cell-lysate (45 µg protein) to a reaction mixture containing GDP-Fuc,
acceptor, 10 mM α-L-Fucose and 10 mM MnCl2 in 50 mM MOPS buffer (pH 7.5). The
mixture was incubated at 37 °C for 2 h. The product was purified by the Sep-PAK C18
isolation procedure (35), and analyzed by liquid scintillation counting. Product formation was
also measured at 0.5, 1 and 2 h and found to be linear in this time range.
Mutation screening by restriction-endonuclease analysis
Genomic DNA isolated from 5 ml EDTA anticoagulated blood according to (36), was
amplified by primers VII-15s and VII-5as. The 338 bp product was used without prior
purification for restriction-enzyme analysis by Not I and electrophoresis on a 1.75 %
SeaKem-agarose gel (FMC), followed by ethidium bromide staining. For Not I restriction-
endonuclease analysis of selected family members the primer pair VII-3s/VII-4as was used
for amplification (generating a 1404 bp product) with 791 and 613 bp cleavage products.
Flow cytometry
Flow cytometric analyses were performed on a FACScan instrument (Becton Dickinson)
operating with CELLQuest software and calibrated with 6 µm CaliBRITE beads with the
13
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
AutoCOMP program (Becton Dickinson). One ml of EDTA-anticoagulated peripheral blood
was diluted into 50 ml lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 90 mM Titriplex III
(Merck p.a.) pH 7.3), allowed to stand in room temperature for 7 min, centrifuged and washed
once with 50 ml PBS, pH 7.2. Leukocytes were resuspended in PBS with 0.1% bovine serum
albumin (BSA, Sigma) to a final concentration of 5-10x106 cells/ ml. Fifty µl of cell
suspensions were incubated with 5 µl of primary antibody (Leu-M1 diluted 1:5; VIM-2
diluted 1:100; KM93 diluted 1:40, CSLEX-1 diluted 1:50) and incubated for 15 min at RT.
Cells were then washed with 2 ml of PBS, resuspended in 55 µl of FITC-conjugated F(ab´)2
fragment of rabbit anti-mouse immunoglobulins diluted 1:10 in PBS and incubated for
another 15 min at room temperature. The cells were washed in PBS and fixed in 200 µl of 1%
paraformaldehyde. Mouse FITC-conjugated IgG1 antibodies were used as negative controls.
Of 5000 cells counted only data on the gated granulocyte population is presented.
Results
Identification of a patient with an abnormal expression of SLex and CD65s on her PMN
PMN lysates were analyzed by Western blot analysis to detect differences in expression of
SLex and CD65s. All PMN samples analyzed from healthy volunteers expressed a similar set
of SLex carrying glycoproteins with most intensely stained bands in the molecular weight
region around 90-115 kDa. A representative sample is shown in Fig. 1, lane B. VIM-2
14
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
antibody directed against the CD65s epitope weakly stained glycoproteins with molecular
weights around 60-70 kDa (Fig. 1, lane D). Western blot analyses of PMN lysates from
patients with ulcerative colitis showed staining patterns comparable to the healthy population.
However one of the patients (M.N.) exhibited a different staining pattern. The Western blot
analysis of PMN lysate from this individual showed a significant reduction in the staining of
SLex-bearing glycoproteins. The staining intensity was about 60% compared to control
samples for identical amounts of total protein (Table I, Fig. 1, lane A). In addition, staining of
one band in the 100 kDa region was selectively lost. This pattern was seen using two different
antibodies (KM-93, CSLEX-1) both known to react with SLex, albeit with somewhat
different binding properties ((37)data not shown). Western blot analysis of PMN lysates from
this patient (M.N.) using the VIM-2 antibody directed against the CD65s epitope, showed an
increased staining (480%) compared to control samples (Fig. 1, Table I). This patient was
analyzed both at the time of active disease and in clinical remission at several occasions
during a two year period. The reduced expression of SLex and elevated expression of CD65s
remained constant during this time.
Lowered SLex expression correlates with a G329A mutation in the gene coding for
Fucosyltransferase VII
The lowered SLex expression in PMN of patient M.N. indicated a potential defect in the Fuc-
TVII enzyme. The gene coding for Fuc-TVII, FUT7, was amplified from genomic DNA by
PCR and TA-cloning. Plasmids were isolated from 13 bacterial clones and sequenced over
15
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
the FUT7 insert. The two exons and the 253 bp intron present in the FUT7 gene were
sequenced in both directions. There were no differences in the intron sequences between the
two alleles from this individual. However, a G329A missense mutation was found in 7 out of
the 13 bacterial clones in exon 2 indicating that M.N. carried this mutation heterozygously in
one allele. The G329A nucleotide change leads to an amino acid shift from arginine to
glutamine at position 110. Sequence alignment (38) showed that FUT7-Arg110 is conserved
in all the 16 α1,3-fucosyltransferases cloned so far from vertebrate species (13,39-41).
Screening for G329A by restriction-endonuclease analysis
A restriction fragment length polymorphism (RFLP) assay was used to screen for the G329A
mutation in DNA preparations from 106 plasma donors in Göteborg and 258 unselected adults
in the Linköping area. In this population three additional individuals carrying the G329A
mutation heterozygously were identified. The overall frequency of the G329A mutation in the
analyzed populations was 0.82%.
Identification of an individual homozygous for the G329A mutation in FUT7
DNA from another of the identified heterozygotes (M.L.) was cloned and sequenced. This
confirmed the presence of the G239A mutation in one allele and no other mutations or
alterations in the coding sequences or in the intron sequence. Not I restriction endonuclease
analysis of M.L. and five of her family members are summarized in Figure 2. Apart from the
16
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
heterozygous individual M.L., her brother (R.J.) and both of her daughters (A.L. and L.L.)
also showed a cleavage pattern consistent with heterozygous expression of the G329A
mutation. Her husband did not carry the G329A mutation. However, the PCR product
obtained from the mother of M.L. (S.J.) was not digested at all, which indicated a
homozygous expression of the G329A mutation (Figure 2). The two FUT7 exons and the
intron were completely sequenced in both directions from 14 clones obtained from this
individual. All clones contained the G329A mutation. No other nucleotide changes were
found. This individual thus carried the isolated mutation in both of her FUT7 alleles. When
PMN lysates prepared from this individual were analyzed by Western blot using antibody
KM93 directed against SLex there was an almost complete lack of expression of SLex
binding glycoproteins compared to control samples (Table I, Figure 3, lanes A and B). When
the same samples were analyzed using the VIM-2 antibody directed against CD65s a marked
increase in the expression of this epitope was found for this individual (Figure 3, lane C). The
increased staining intensity was 980% compared to control samples (Table I, Figure 3, lane D)
and 205% compared to individual M.N.
Flow cytometry analysis of PMN from the individual homozygous for the G329A mutation in
FUT7
The expression of SLex on PMN from individuals with or without the G329A mutation was
investigated using flow cytometry. Most of the PMN from the homozygous individual (S.J.)
showed a KM93 staining just above background. However, a sub-population of cells from
17
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
this individual showed an intermediate staining with this antibody. Antibody KM93 reacted
strongly with PMN from an individual lacking the G329A mutation (Fig. 4a). Staining of
PMN with the anti-SLex antibody CSLEX-1 showed the same pattern with lower expression
for the homozygous individual and a higher expression for an individual lacking the G329A
mutation (Fig. 4b). In contrast to the results obtained by Western blot there was no major
differences between these individuals in staining of PMN with the anti-CD65s antibody
VIM-2 (Fig. 4c). As expected PMN from all analyzed individuals expressed a high level of
Lex (Fig. 4d). Sialidase treatment of PMN prior to flow cytometry analysis reduced binding
of KM93, CSLEX-1 and VIM-2 antibodies to background levels (data not shown).
Cell surface expression of SLex is not detected on COS-7 cells transfected with FUT7
G329A cDNA
The Western blot and flow cytometry analyses of PMN from hetero- and homozygously
mutated individuals indicated that the Arg 110→Gln substitution affects Fuc-TVII activity.
To confirm this, COS-7 cells were transiently transfected with plasmids containing either the
mutated or the wild type FUT7 cDNA sequence (pSI-329 and pSI-wt, respectively). Mock
transfectants using vector only (pSI) was used as negative controls. After transfection the
expression of SLex, CD65s, Lex and SLea were analyzed by immunofluorescence staining.
Cells transfected with pSI-wt were clearly stained with anti-SLex antibody (Fig. 5A),
whereas there was no staining of cells transfected with pSI-329 with this antibody (Fig. 5B).
18
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
The same pattern was seen using both KM-93 and CSLEX-1 antibodies (data not shown).
This indicated that the G329A mutation significantly reduces the activity of Fuc-TVII in
transfected COS-7 cells. Neither of the transfectants was stained with antibodies directed
against SLea, CD65s or Lex.
Fucosyltransferase VII activity is not detected in COS-7 cells transfected with FUT7 G329A
cDNA.
Fuc-TVII activity was analyzed using sialylated type 1 and 2 acceptors and whole cell lysates
of COS-7 cells transfected with pSI-wt, pSI-329 or pSI. The pSI-wt construct produced an
active enzyme whereas there was no detectable enzyme activity in cells transfected with the
mutated construct or vector only (Table II), in accordance with the immunofluorescence
results. When a sialylated type 1 chain acceptor was used, no activity was detected in either of
the transfectants. As a measure of transfection efficiency RNA was isolated from the
transfected cells and a fragment of the FUT7 transcript was amplified using quantitative real-
time RT-PCR analysis. There were no quantitative differences in FUT7 mRNA between pSI-
wt and pSI-329 transfected cells (Table III). This pattern was seen for all transfection
experiments used for Fuc-TVII activity measurements. All values were corrected for
differences in total mRNA content using amplification of β-actin mRNA as an internal
control in each experiment (Table III).
Expression of the Fuc-TVII enzyme in transfected COS-7 cells
19
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
COS-7 cells transfected with pSI-wt, pSI-329, or pSI were analyzed by Western blot using
purified antiserum against the Fuc-TVII enzyme. The antiserum stained a band with a
molecular weight of 39 kDa with similar intensity in cells transfected with pSI-wt and pSI-
329, whereas this band was not detected in mock-transfected (pSI) cells (Fig 6). The
molecular weight of the stained band corresponds to the molecular weight previously reported
for FucT-VII (12). In addition a specific band with an apparent molecular weight of 55 kDa
was stained in pSI-wt transfected cells. This band was not detected in either pSI-329 or pSI
transfected cells (Fig. 6).
Discussion
When analyzing the expression of SLex and SLex-related antigens on PMN from patients
with ulcerative colitis one patient with decreased expression of SLex was identified. The
FUT7 gene of this individual was cloned and sequenced and a single point mutation, G329A,
was found in one of the alleles. This mutation gives an amino acid shift from an arginine to a
glutamine at position 110 in Fuc-TVII (Arg110→Gln). When the G329A mutation was
screened for in two small Swedish populations 3 out of 364 individuals were found
heterozygous for this mutation (Fuc-TVII R/Q). Although a larger population needs to be
examined to ascertain the exact overall frequency of this mutation, this indicates that it might
be carried by approximately 1% of the population. FUT7 should thus be considered to be a
polymorphic gene; especially since the G329A allele might be only one of several mutated
alleles to be found in various populations around the world. Genetic analysis of the family
20
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
members of one of the identified heterozygotes revealed an individual carrying the G329A
mutation in both alleles (Fuc-TVII Q/Q). The two exons and the 253 bp intron of FUT7 (33)
were fully sequenced in two of the identified heterozygotes (M.N. and M.L.) and in the
homozygote. Apart from the G329A mutation there was no other structural alteration
compared to the wild type FUT7 sequence.
Western blot analysis of PMN lysates and flow cytometry of PMN showed that individuals
carrying the G329A mutation had a lowered expression of SLex, which is consistent with that
the G329A mutation affects Fuc-TVII activity. Western blot analysis of PMN lysates from
individuals carrying the G329A mutation also showed an increased staining of CD65s. Flow
cytometry analysis of PMN from the Fuc-TVII Q/Q individual also indicated an increased
surface expression of CD65s compared to Fuc-TVII R/R individuals. However the increase
was not as pronounced as seen in the Western blot analysis. Since there is a possible
competition between Fuc-TVII, Fuc-TIV and Fuc-TIX for the same sialylated
polylactosamine acceptor substrate a lowered activity of Fuc-TVII would theoretically
increase the substrate availability for Fuc-TIV and Fuc-TIX, which would explain the
observed increase in CD65s expression (Fig. 7). Surprisingly, the major increase in CD65s
antigens was detected on proteins in the 60-70 kDa region whereas the expression of SLex
was mainly detected on proteins migrating in the 90-115 kDa region. This would suggest
that the observed phenotypic changes are not only explained by substrate availability.
Previous studies have shown a reciprocal expression of Fuc-TVII and Fuc-TIV during
21
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
differentiation of HL60 cells and in HL60 cells deficient in FUT7 expression (42,43),
indicating a linked transcriptional regulation of these enzymes. The possible effect of the
FUT7 mutation on the transcriptional levels of fucosyltransferases in PMN needs to be further
studied. Furthermore, there is always a possibility that the analyzed individuals in this study
may have other differences in glycosyltransferase activity in addition to the lowered activity
of Fuc-TVII, which would affect the glycoprotein profiles obtained in the Western blot
analysis.
The phenotypic changes observed in individuals carrying the G329A mutation suggested a
decreased activity of the Fuc-TVII enzyme. To study the effect of the G329A mutation in
more detail COS-7 cells were transfected with wild type and mutated FUT7 constructs.
COS-7 cells transfected with the FUT7 gene containing the G329A mutation did not express
SLex on the cell surface in contrast to cells transfected with the wild type FUT7 construct. In
addition there was no detectable α1,3-fucosyltransferase activity in whole cell lysate of
COS-7 cells transfected with the mutated construct when an α2,3-sialylated lactosamine
acceptor was used as substrate. The reported Km values of Fuc-TVII is in the low millimolar
range when Neu5Acα2-3Galβ1-4GlcNAc is used as acceptor (44,45). The obtained Km
value for the sialylated type 2 acceptor used in the present study was 6 mM. Km for GDP-
Fuc was 5 µM. An acceptor concentration of 10 mM and a GDP-Fuc concentration of 100
µM would ensure an individual reaction rate at saturating acceptor concentrations but still
there was no detectable activity in the cells transfected with the pSI-329 construct. Even
22
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
when incubation with the cell lysate was prolonged to 18 h the activity in the COS-7 cell
transfected with the mutant construct gave the same incorporation as the mock-transfected
COS-7 cells, indicating that the Arg 110→Gln substitution inactivates the Fuc-TVII enzyme.
There was an over-expression of FUT7 transcripts in both cells transfected with the wild
type and mutated constructs and the levels of transcripts were similar for both constructs. This
indicates that the decrease in enzymatic activity in the COS-7 cells was not an effect of
reduced transcription efficiency for the mutated FUT7 construct. The lack of activity when a
α2,3-sialylated type 1 chain was used as acceptor was to be expected as only Fuc-TVII was
overexpressed in the COS-7 cells and this enzyme specifically recognizes only the sialylated
type 2 chain acceptor (11,12,15,44).
Western blots using the polyclonal anti Fuc-TVII antiserum positively identified the expected
39 kDa band in pSI-wt and pSI-329 transfected cells in about equal quantities. Interestingly,
the cells transfected with pSI-wt, but not those transfected with pSI-329, showed an
additional specific band at 55 kDa. This heavier band might correlate to a hetero-dimer or a
highly glycosylated form of the enzyme and imposes an interesting question on the structural
and functional consequences of the G329A mutation. The molecular explanation for the lack
of this band is now under focus and will be the subject of a separate publication.
Sequence alignment showed that Fuc-TVII-Arg110 is conserved in all the 16 α1,3-
fucosyltransferases cloned so far from vertebrate species (18,39,40). This amino acid is found
23
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
just in-between the hypervariable regions of α1,3-fucosyltransferases considered to be
responsible for the acceptor binding domain and the peptide motifs presumed to be involved
in the GDP-fucose binding (41). This arginine residue has not before been directly linked to
enzymatic activity or specificity. It remains to be studied whether the Arg110→Gln
substitution directly affects enzyme activity or if the substitution affects other functions of the
enzyme such as ER or Golgi retention and degradation. One of the naturally occurring
mutations found to inactivate the Lewis enzyme (Fuc-TIII) has been found to induce
susceptibility to protease digestion rather than directly affecting enzymatic-binding sites (46).
The role of Fuc-TVII in the synthesis of selectin ligands has been demonstrated in vitro using
antisense oligonucleotides (19). The role of Fuc-TVII in vivo has also been clearly indicated
by the generation of mice completely deficient in this enzyme (20). These mice showed blood
leukocytosis, non existent binding of leukocytes to E- and P-selectin, impaired neutrophil
trafficking in inflammation, and defects in lymphocyte recirculation. However Fuc-TVII
deficient mice did not develop a phenotype as severe as mice deficient in E- and P-selectin.
E/P-selectin deficient mice exhibit extreme leukocytosis, systemic infections and plasma cell
proliferation (47) implying that lack of Fuc-TVII would not completely abolish all functional
selectin ligands. The role of Fuc-TIV in generating selectin ligands has been debated.
However recent studies on mice deficient in Fuc-TVII and/or Fuc-TIV support a role for
Fuc-TIV in selectin dependent adhesion of leukocytes (48). Although Fuc-TVII seems to
24
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
play the major role in generating selectin ligands it is clear that inactivation of both Fuc-TVII
and Fuc-TIV is needed to completely inhibit leukocyte adhesion to activated endothelium. In
addition several studies have shown that specific cell lines can synthesize selectin ligands
upon transfection with only Fuc-TIV (49-52). Studies using HL60 cells have also shown that
CD65s can act as a ligand for E-selectin in in vitro flow systems (53). We are currently
analyzing PMN from Fuc-TVII Q/Q and Fuc-TVII R/Q individuals in a selectin adhesion
assay under dynamic flow conditions to address these questions.
The phenotype that can be related to neutrophil dysfunction in the Fuc-TVII deficient mice is
similar to some of the clinical symptoms of patients with the disease called leukocyte
adhesion deficiency type II (LAD II). LAD II patients and Fuc-TVII deficient mice both have
raised leukocyte counts and impaired neutrophil rolling on E- and P-selectins. But in contrast
to Fuc-TVII deficient mice, LAD II patients also suffer from an increased incidence of
bacterial infections in early infancy. In addition, LAD II patients exhibit growth and mental
retardation (54,55). The LAD II deficiency affects all fucosylated glycoconjugates including
the selectin ligands. Recently, a mutation in a GDP-fucose transporter has been implied as
responsible for the LAD II phenotype (56). Thus the clinical symptoms in LAD II patients
cannot be attributed to a specific deficiency in selectin ligand synthesis alone but reflects a
general deficiency of fucose metabolism and transport. The individual homozygously mutated
in FUT7 and presented in this paper is diagnosed with ulcer disease, non-insulin dependant
diabetes, osteoporosis, spondyloarthrosis and Sjögren´s syndrome. The latter diagnosis was
confirmed by signs of keratoconjunctivitis sicca, sialoadenitis and a positive titer for anti-
25
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
nuclear antibodies. There was however no history of recurrent bacterial infections and the
white blood cell count was repeatedly within the reference range thus excluding a phenotype
similar to LAD II for this patient. Nor have any consistent medical conditions associated with
impaired neutrophil function been reported for the heterozygous members of this patient’s
family.
26
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Footnotes
1This study was supported by grants from the Swedish Medical Research Council (MFR 0002
and MFR 8266), University Hospital Governmental grants and grants from the Swedish
Foundation for Strategic Research (A.L. and G.L.).
2Abbreviations: HEV, high endothelial venules; SLex, sialyl Lewis x; SLea, sialyl Lewis a;
Lex, Lewis x; Fuc-T, fucosyltransferase; PMN, polymorphonuclear leukocytes; LAD II.
Leukocyte adhesion deficiency type II.
Acknowledgement
We thank Dr. Sven Almer and Professor Peter Söderkvist for providing patient and DNA
samples. We also thank Ammi Grahn and Anna-Kristina Granath for excellent technical
assistance and Dr. Anders Elmgren for helpful discussions.
27
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
References
1. Springer, T. A. (1994) Cell 76, 301-314
2. Lasky, L. A. (1995) Annu Rev Biochem 64, 113-139
3. Kansas, G. S. (1996) Blood 88, 3259-3287
4. Varki, A. (1994) Proc Natl Acad Sci U S A 91, 7390-7397
5. Swarte, V. V., Joziasse, D. H., Van den Eijnden, D. H., Petryniak, B., Lowe, J.
B., Kraal, G., and Mebius, R. E. (1998) Eur J Immunol 28, 3040-3047
6. Foxall, C., Watson, S. R., Dowbenko, D., Fennie, C., Lasky, L. A., Kiso, M.,
Hasegawa, A., Asa, D., and Brandley, B. K. (1992) J Cell Biol 117, 895-902
7. Holmes, E. H., Ostrander, G. K., and Hakomori, S. (1986) J Biol Chem 261,
3737-3743
8. Goelz, S. E., Hession, C., Goff, D., Griffiths, B., Tizard, R., Newman, B., Chi-
Rosso, G., and Lobb, R. (1990) Cell 63, 1349-1356
9. Lowe, J. B., Kukowska-Latallo, J. F., Nair, R. P., Larsen, R. D., Marks, R. M.,
Macher, B. A., Kelly, R. J., and Ernst, L. K. (1991) J Biol Chem 266, 17467-
17477
10. Kumar, R., Potvin, B., Muller, W. A., and Stanley, P. (1991) J Biol Chem 266,
21777-21783
11. Natsuka, S., Gersten, K. M., Zenita, K., Kannagi, R., and Lowe, J. B. (1994) J
Biol Chem 269, 16789-16794
12. Sasaki, K., Kurata, K., Funayama, K., Nagata, M., Watanabe, E., Ohta, S.,
Hanai, N., and Nishi, T. (1994) J Biol Chem 269, 14730-14737
28
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
13. Kaneko, M., Kudo, T., Iwasaki, H., Ikehara, Y., Nishihara, S., Nakagawa, S.,
Sasaki, K., Shiina, T., Inoko, H., Saitou, N., and Narimatsu, H. (1999) FEBS
Lett 452, 237-242
14. Grabenhorst, E., Nimtz, M., Costa, J., and Conradt, H. S. (1998) J Biol Chem
273, 30985-30994
15. Niemela, R., Natunen, J., Majuri, M. L., Maaheimo, H., Helin, J., Lowe, J. B.,
Renkonen, O., and Renkonen, R. (1998) J Biol Chem 273, 4021-4026
16. Wagers, A. J., Lowe, J. B., and Kansas, G. S. (1996) Blood 88, 2125-2132
17. Knibbs, R. N., Craig, R. A., Natsuka, S., Chang, A., Cameron, M., Lowe, J. B.,
and Stoolman, L. M. (1996) J Cell Biol 133, 911-920
18. Smith, P. L., Gersten, K. M., Petryniak, B., Kelly, R. J., Rogers, C., Natsuka, Y.,
Alford, J. A., 3rd, Scheidegger, E. P., Natsuka, S., and Lowe, J. B. (1996) J Biol
Chem 271, 8250-8259
19. Hiraiwa, N., Dohi, T., Kawakami-Kimura, N., Yumen, M., Ohmori, K., Maeda,
M., and Kannagi, R. (1996) J Biol Chem 271, 31556-31561
20. Maly, P., Thall, A., Petryniak, B., Rogers, C. E., Smith, P. L., Marks, R. M.,
Kelly, R. J., Gersten, K. M., Cheng, G., Saunders, T. L., Camper, S. A.,
Camphausen, R. T., Sullivan, F. X., Isogai, Y., Hindsgaul, O., von Andrian, U.
H., and Lowe, J. B. (1996) Cell 86, 643-653
21. Nishihara, S., Narimatsu, H., Iwasaki, H., Yazawa, S., Akamatsu, S., Ando, T.,
Seno, T., and Narimatsu, I. (1994) J Biol Chem 269, 29271-8
22. Mollicone, R., Reguigne, I., Kelly, R. J., Fletcher, A., Watt, J., Chatfield, S.,
29
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Aziz, A., Cameron, H. S., Weston, B. W., and Lowe, J. B. (1994) J Biol Chem
269, 20987-20994
23. Elmgren, A., Mollicone, R., Costache, M., Borjeson, C., Oriol, R., Harrington,
J., and Larson, G. (1997) J Biol Chem 272, 21994-21998
24. Pang, H., Liu, Y., Koda, Y., Soejima, M., Jia, J., Schlaphoff, T., Du Toit, E. D.,
and Kimura, H. (1998) Hum Genet 102, 675-680
25. Mollicone, R., Reguigne, I., Fletcher, A., Aziz, A., Rustam, M., Weston, B. W.,
Kelly, R. J., Lowe, J. B., and Oriol, R. (1994) J Biol Chem 269, 12662-12671
26. Larson, G., Borjeson, C., Elmgren, A., Kernholt, A., Henry, S., Fletcher, A.,
Aziz, A., Mollicone, R., and Oriol, R. (1996) Vox Sang 71, 233-241
27. Elmgren, A., Borjeson, C., Mollicone, R., Oriol, R., Fletcher, A., and Larson, G.
(2000) Hum Mutat 16, 473-81.
28. Pang, H., Koda, Y., Soejima, M., Schlaphoff, T., du Toit, E. D., and Kimura, H.
(1999) Ann Hum Genet 63, 277-84.
29. Larson, G., Svensson, L., Hynsjö, L., Elmgren, A., and Rydberg, L. (1999) Vox
Sang 77, 227-236
30. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H.,
Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D.
C. (1985) Anal Biochem 150, 76-85
31. Laemmli, U. K. (1970) Nature 227, 680-685
32. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc Natl Acad Sci U S A 76,
4350-4354
30
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
33. Winder, A., Smithers, N., Witham, S., Symons, A., and Edbrooke, M. (1995)
Biochem Soc Trans 23, 165S
34. Davis, L. G., Dibner, M. D., and Battey, J. F. (1986) Elsevier Science Publishing
Co., New York
35. Mollicone, R., Gibaud, A., Francois, A., Ratcliffe, M., and Oriol, R. (1990) Eur
J Biochem 191, 169-176
36. Miller, S. A., Dykes, D. D., and Polesky, H. F. (1988) Nucleic Acids Res 16,
1215
37. Dohi, T., Nemoto, T., Ohta, S., Shitara, K., Hanai, N., Nudelman, E., Hakomori,
S., and Oshima, M. (1993) Anticancer Res 13, 1277-82.
38. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) Nucleic Acids Res
22, 4673-4680
39. Costache, M., Apoil, P. A., Cailleau, A., Elmgren, A., Larson, G., Henry, S.,
Blancher, A., Iordachescu, D., Oriol, R., and Mollicone, R. (1997) J Biol Chem
272, 29721-8
40. Kageyama, N., Natsuka, S., and Hase, S. (1999) J Biochem (Tokyo) 125, 838-
845
41. Dupuy, F., Petit, J. M., Mollicone, R., Oriol, R., Julien, R., and Maftah, A.
(1999) J Biol Chem 274, 12257-62.
42. Clarke, J. L., and Watkins, W. M. (1997) Glycobiology 7, 835-46.
43. Weston, B. W., Hiller, K. M., Mayben, J. P., Manousos, G., Nelson, C. M.,
Klein, M. B., and Goodman, J. L. (1999) Eur J Haematol 63, 42-9.
31
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
44. Britten, C. J., van den Eijnden, D. H., McDowell, W., Kelly, V. A., Witham, S.
J., Edbrooke, M. R., Bird, M. I., de Vries, T., and Smithers, N. (1998)
Glycobiology 8, 321-7
45. Shinoda, K., Morishita, Y., Sasaki, K., Matsuda, Y., Takahashi, I., and Nishi, T.
(1997) J Biol Chem 272, 31992-7
46. Nishihara, S., Hiraga, T., Ikehara, Y., Iwasaki, H., Kudo, T., Yazawa, S.,
Morozumi, K., Suda, Y., and Narimatsu, H. (1999) Glycobiology 9, 373-382
47. Frenette, P. S., Mayadas, T. N., Rayburn, H., Hynes, R. O., and Wagner, D. D.
(1996) Cell 84, 563-74.
48. Weninger, W., Ulfman, L. H., Cheng, G., Souchkova, N., Quackenbush, E. J.,
Lowe, J. B., and von Andrian, U. H. (2000) Immunity 12, 665-76.
49. Goelz, S., Kumar, R., Potvin, B., Sundaram, S., Brickelmaier, M., and Stanley,
P. (1994) J Biol Chem 269, 1033-40
50. Wagers, A. J., Stoolman, L. M., Kannagi, R., Craig, R., and Kansas, G. S.
(1997) J Immunol 159, 1917-29
51. Zollner, O., and Vestweber, D. (1996) J Biol Chem 271, 33002-8.
52. Huang, M. C., Zollner, O., Moll, T., Maly, P., Thall, A. D., Lowe, J. B., and
Vestweber, D. (2000) J Biol Chem 275, 31353-60
53. Handa, K., Stroud, M. R., and Hakomori, S. (1997) Biochemistry 36, 12412-
12420
54. Etzioni, A., Frydman, M., Pollack, S., Avidor, I., Phillips, M. L., Paulson, J. C.,
and Gershoni-Baruch, R. (1992) N Engl J Med 327, 1789-1792
32
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
55. Phillips, M. L., Schwartz, B. R., Etzioni, A., Bayer, R., Ochs, H. D., Paulson, J.
C., and Harlan, J. M. (1995) J Clin Invest 96, 2898-2906
56. Luhn, K., Wild, M. K., Eckhardt, M., Gerardy-Schahn, R., and Vestweber, D.
(2001) Nat Genet 28, 69-72.
57. Handa, K., Withers, D. A., and Hakomori, S. (1998) Biochem Biophys Res
Commun 243, 199-204
33
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Figure legends
Figure 1
Western blot analysis of lysed PMN isolated from a patient with ulcerative colitis (M.N.)
(lane A and C) and a control sample (lane B and D). Each lane was loaded with 25 µg of
protein. The blots were probed with antibodies against SLex (KM93, lanes A and B) and
CD65s (VIM-2, lanes C and D). Molecular weight standards are indicated to the left.
Figure 2
Restriction endonuclease analyses of individual M. L. and her family. Squares denote males
and circles denote females. The completely filled circle denotes the Fuc-TVII Q/Q individual
(S.J.). Half-filled symbols denote Fuc-TVII R/Q individuals and the open square denotes a
Fuc-TVII R/R individual. A slash across the symbol indicates that the person is deceased.
The agarose gel electrophoresis pattern of each individual after Not I digestion of the 1404 bp
product is shown below each symbol. The G329A mutated allele is not digested, whereas the
wild type allele is digested into two fragments of 791 and 613 bp.
Figure 3
Western blot analysis of lysed PMN isolated from the Fuc-TVII Q/Q individual (S.J.) (lane A
and C) and a control sample (lane B and D). Each lane was loaded with 20 µg of protein.
The blots were probed with antibodies against SLex (KM93, lanes A and B) and CD65s
34
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
(VIM-2, lanes C and D). Molecular weight standards are indicated to the left.
Figure 4
Flow cytometry analysis of isolated PMN from the FucT-VII Q/Q individual (S.J.) (gray
histograms) and a FucT-VII R/R individual (white histograms). Negative control is shown as
black histograms. A, KM93 antibody; B, CSLEX-1 antibody; C, VIM-2 antibody; D, Anti-
Lex antibody.
Figure 5
Immunostaning of COS-7 cells transfected with pSI-wt (A) and pSI-329 (B). Transfected
cells were incubated with primary antibody against SLex (KM-93) and fluorescein
conjugated rat anti mouse IgG secondary antibody.
Figure 6
Western blot analysis of transfected COS-7 cell lysates using antiserum directed against the
Fuc-TVII enzyme. Cells transfected with pSI-wt (Lane A), pSI-329 (Lane B) and pSI alone
(Lane C). Molecular weight standards are indicated to the left.
35
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Figure 7
Biosynthetic pathway for the SLex and CD65s epitopes from a sialylated polylactosamine
precursor (15,57).
36
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Table I
Densitometry analysis of Western blots (integrated optical density)PMN lysates SLex (KM93) CD65s (VIM-2)
M.N. 100A 100A
S.J. 0.2 205.0
Controls(n=10, mean ± SD)
169.3±22.2 20.9±17.5
A Value set to 100
37
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Table II
Analysis of Fucosyltransferase VII activity Specific Activity
(pmol/(min*mg prot))Km acceptora
(mM)
Km GDP-Fuc
(µM)
pSI-wt 10.5 ± 1.3 6.0 ±0.8 5.0 ±0.4
pSI-329 ndb - -
pSI nd - -
COS-7 cells transfected with pSI-wt, pSI-329 or pSI were lysed and aliquots
corresponding to 45 µg protein were used to measure the fucosyltransferase
activity by analyzing the incorporation of GDP-[14C] fucose to the acceptor
substrate. The values are mean values of three experiments ± SD.
a NeuAcα2-3Galβ1-4GlcNAc-O-biotin (10 mM)
b nd=not detectable
38
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Table III
Analysis of mRNA content, number of cycles before ∆Rn reaches the threshold*
Data from two different transfections are shown.
FUT7 ß-actin
mean SD mean SD
pSI 40.00 0.00 18.16 0.54
pSI-wt 30.37 0.05 17.32 0.09
pSI-329 29.80 0.50 17.62 0.13
pSI 40.00 0.00 17.64 0.04
PSI-wt 31.22 0.29 17.86 0.11
pSI-329 30.06 0.70 18.23 0.05
*Threshold (∆Rn) set to 0.05
39
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
Per Bengtson, Cecilia Larson, Arne Lundblad, Göran Larson and Peter PåhlssonIdentification of a missense mutation (G329A; Arg110-Gln) in the human FUT7 gene
published online June 12, 2001J. Biol. Chem.
10.1074/jbc.M104165200Access the most updated version of this article at doi:
Alerts:
When a correction for this article is posted•
When this article is cited•
to choose from all of JBC's e-mail alertsClick here
by guest on March 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from